SEC Form 10-Q filed by Prelude Therapeutics Incorporated
$PRLD
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2024 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 6/20/2024 | $3.00 | Equal Weight → Underweight | Barclays |
| 3/13/2024 | $7.00 | Mkt Outperform | JMP Securities |
| 2/20/2024 | $5.00 | Buy → Neutral | H.C. Wainwright |
| 12/19/2023 | $10.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 11/21/2022 | $8.00 → $6.00 | Neutral → Underperform | BofA Securities |
| 9/9/2022 | $19.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/29/2022 | $9.00 | Buy | Jefferies |
10-Q - Prelude Therapeutics Inc (0001678660) (Filer)
8-K - Prelude Therapeutics Inc (0001678660) (Filer)
SCHEDULE 13G - Prelude Therapeutics Inc (0001678660) (Subject)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
3 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial leadership and investment banking. "Katina brings to Prelude an abundance of experience as a strategic and financial advisor to our leadership team," stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. "We welcome her to our board and we look forward to
Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development pipeline progress. "Prelude continues to make great progress in discovering and advancing a diverse pipeline of differentiated small molecu
Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives for 2022: Focused on demonstrating proof-of-concept clinical data for lead pipeline compounds and continued advancement of Prelude's diverse precision oncology pipeline Cash runway guidance extended to 2H/2024 WILMINGTON, Del., March 16, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2021. "With Prelude's core competencies in cancer biology an
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 2027 based on preliminary estimates Company to host investor conference call and webcast on Wednesday, November 12, 2025 at 8:00 AM EST WILMINGTON, Del., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Prelude T
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company's preliminary estimates, and potentially into the third quarter of 2028 if Incyte exercises option on JAK2 program Company to release third quarter 2025 financial results and conduct an investor conference call on November 12, 2025 WILMIN
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net salesPrelude will continue to develop all JAK2V617F program assets during the option period; if optioned, Incyte would lead development and commercialization globally WILMINGTON, Del., Nov. 04, 2025
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
4 - Prelude Therapeutics Inc (0001678660) (Issuer)
H.C. Wainwright upgraded Prelude Therapeutics from Neutral to Buy and set a new price target of $5.00
Barclays downgraded Prelude Therapeutics from Equal Weight to Underweight and set a new price target of $3.00
JMP Securities initiated coverage of Prelude Therapeutics with a rating of Mkt Outperform and set a new price target of $7.00
SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)
SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 2027 based on preliminary estimates Company to host investor conference call and webcast on Wednesday, November 12, 2025 at 8:00 AM EST WILMINGTON, Del., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Prelude T
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company's preliminary estimates, and potentially into the third quarter of 2028 if Incyte exercises option on JAK2 program Company to release third quarter 2025 financial results and conduct an investor conference call on November 12, 2025 WILMIN
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation - At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events - Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the first interim clinical